Haemonetics to Buy Attune Medical for $160 Million

Haemonetics has begun a deal to acquire privately-held, Chicago-based Attune Medical.
 
Attune Medical is the maker of the ensoETM proactive esophageal cooling device. ensoETM, according to Attune, is the only U.S. Food and Drug Administration (FDA)-cleared temperature regulation device for esophageal protection during radiofrequency (RF) cardiac ablation.
 
RF cardiac ablation is commonly used to treat atrial fibrillation (AFib). ensoETM reduces the chance of esophageal injury during RF cardiac ablations and further studies have shown lower procedure times and readmissions. The company also touted higher rates of same-day discharge and long-term procedure success using ensoETM.
 
The acquisition deal is valued at an upfront cash payment of $160 million at closing, with further consideration based on sales growth in the three years following. Haemonetics expects the deal to be completed in Q1 of its fiscal year 2025.
 
Stewart Strong, Haemonetics’ president of Global Hospital said that ensoETM will fortify the company’s presence in the electrophysiology market and complement its leadership in vascular closure.
 
“EnsoETM effectively reduces esophageal injuries without requiring hospitals to purchase complex and costly new ablation systems,” Strong told the press. “With this groundbreaking solution we look forward to empowering more physicians to improve patient outcomes, and expanding our EP portfolio with yet another industry-leading technology to accelerate the growth and impact of our Interventional Technologies business.”
 
Attune Medical pocketed about $22 million in revenue during its fiscal year 2023, which was over double its revenue from the previous fiscal year. Haemonetics expects the transaction to be immediately accretive to its revenue.
 
Attune’s CEO Jay Istvan said, “We are thrilled to become part of Haemonetics. Their Hospital business has strong positions in both EP and critical care, and their international channels are robust and expanding. We believe Haemonetics is the best company to bring ensoETM’s substantial benefits to more caregivers worldwide to enable new standards of care.”
 
Haemonetics closed its $255 million acquisition of cardiac optical technology firm OpSense in December 2023.